Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis

Ciccarelli, Gea; Giuseppe, Gianfranco Di; Cinti, Francesca; Moffa, Simona; Mezza, Teresa; Giaccari, Andrea

doi:10.1002/dmrr.3668

Cited by 3 publications

(1 citation statement)

References 158 publications

(218 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-alcoholic fatty liver disease (NAFLD) is a rapidly increasing metabolic disorder worldwide, characterized by excessive accumulation of fat in the liver without a significant history of alcohol consumption, affecting approximately 24% of the global population (Jiang X, Hu R, Huang Y, et al, 2023). With the rising prevalence of obesity, type 2 diabetes, and metabolic syndrome, NAFLD has emerged as a significant concern in clinical and public health domains (Ciccarelli G, Di Giuseppe G, Cinti F, Moffa S, Mezza T & Giaccari A, 2023). Although NAFLD is generally considered a benign condition, it can progress to non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma, among other serious consequences.…”

Section: Introductionmentioning

confidence: 99%

Bibliometric Analysis of Vitamin D and Non-Alcoholic Fatty Liver Disease

Wang

Chang

2023

JIMR

View full text Add to dashboard Cite

Background: The relationship between vitamin D and non-alcoholic fatty liver disease (NAFLD) has been a subject of significant interest. This study aimed to assess the current research status of vitamin D and NAFLD through a systematic analysis using bibliometric methods. Methods: A search of the Web of Science Core Collection database was conducted to identify relevant literature meeting the study criteria. Key information such as the number of publications, authors, countries, and keywords was extracted. Results: A total of 416 articles were included for analysis. The findings revealed an increasing trend in research on vitamin D and NAFLD in recent years. The dominant forces in the field were concentrated in China and the United States. A few institutions contributed to the majority of the research output, and the research topics primarily covered the association between vitamin D and NAFLD in terms of disease risk, severity, and treatment efficacy. Conclusion: The bibliometric analysis of the literature in this study provided insights into the current status and trends of research on vitamin D and NAFLD. These findings are of significant importance in guiding future research directions and collaborations, offering new perspectives and strategies for the prevention and treatment of NAFLD. Further research should delve into the mechanisms underlying the association between vitamin D and NAFLD, and more clinical trials should be conducted to evaluate the potential role of vitamin D in the treatment of NAFLD.

show abstract

Section: Introductionmentioning

confidence: 99%

Bibliometric Analysis of Vitamin D and Non-Alcoholic Fatty Liver Disease

Wang

Chang

2023

JIMR

View full text Add to dashboard Cite

show abstract

Objective measures of cardiometabolic risk and advanced fibrosis risk progression in primary care patients with metabolic dysfunction-associated steatotic liver disease.

Schreiner,

Zhang,

Moran

et al. 2024

Endocrine Practice

View full text Add to dashboard Cite

Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)

Kostitska,

Protas,

Petrovska

2023

DOMS

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (MAFLD) is recognised worldwide as a serious health problem, given the global prevalence of about 30% of the world population and high incidence of nonalcoholic steatohepatitis (NASH), which has reached epidemic levels in the 12%-21% of people with type 2 diabetes mellitus (DM). In patients with comorbidity of type 2 DM, atherosclerotic cardiovascular disease (ASCVD), visceral obesity (VO), insulin resistance syndrome (IRS) the frequency of MAFLD is 70%. For this reason a modern, complex and patient-oriented approach to the treatment of MAFLD is of paramount importance, which can simultaneously treat several disorders by preventing interaction between underlying causes of NASH in patients with type 2 DM. The growing burden of morbidity, therapeutic inertia of primary care physicians and highly specialized gastroenterologists, endocrinologists regarding early diagnostics of NASH in people with type 2 DM and VO often leads to incomplete treatment of MAFLD manifestations. Nowadays SGLT-2 inhibitors present an innovative class of hypoglycemic drugs which have improved the glucose-centric approach to the therapy of type 2 DM combined with organ-protective properties. The data obtained from epoch-making controlled clinical trials and clinical practice presents an opportunity of new clinical horizons regarding the hepatoprotective properties of SGLT-2 inhibitors. In this review the efficacy, safety and prospects of using SGLT-2 in patients with MAFLD were evaluated.

show abstract

Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis

Cited by 3 publications

References 158 publications

Bibliometric Analysis of Vitamin D and Non-Alcoholic Fatty Liver Disease

Bibliometric Analysis of Vitamin D and Non-Alcoholic Fatty Liver Disease

Objective measures of cardiometabolic risk and advanced fibrosis risk progression in primary care patients with metabolic dysfunction-associated steatotic liver disease.

Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)

Contact Info

Product

Resources

About